The British biotech recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection.
MitoRx Therapeutics are developing first-in-class, mitochondrial-targeted sulfide-donor therapies designed to
• restore cellular energy
• drive fat loss
• protect muscle
They recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection.
At London Life Sciences Week, CEO and fellow Brit Jon Rees sat down with me for the full scoop.
I hope you enjoy watching!
Yours sincerely,
Dr. Adil Ali
Nuvation is gaining real momentum after its first FDA approval, with IBTROZI now treating a growing number of patients with ROS1-positive lung cancer.
Fresh momentum from Jefferies and a new $150 million non-dilutive financing has extended its runway into 2027.
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
